Compile Data Set for Download or QSAR

Found 234 hits Enz. Inhib. hit(s) with all data for entry = 7334   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189942 (US9175003, 27) Show SMILES OC(=O)[C@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)NC(=O)[C@@H]1Cc2cc3OCC(Oc3cc2CN1C(=O)c1ccoc1)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H35Cl2N3O8/c47-37-14-5-29(17-38(37)48)24-57-36-12-10-32(11-13-36)43-26-58-41-20-34-19-40(51(23-35(34)21-42(41)59-43)45(53)33-15-16-56-25-33)44(52)50-39(46(54)55)18-27-1-6-30(7-2-27)31-8-3-28(22-49)4-9-31/h1-17,20-21,25,39-40,43H,18-19,23-24,26H2,(H,50,52)(H,54,55)/t39-,40-,43?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	843	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189943 (US9175003, 31) Show SMILES OC(=O)[C@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)NC(=O)[C@@H]1Cc2cc3OCC(Oc3cc2CN1Cc1ccccc1C#N)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H38Cl2N4O6/c50-41-18-9-32(19-42(41)51)28-59-40-16-14-35(15-17-40)47-29-60-45-22-38-21-44(55(27-39(38)23-46(45)61-47)26-37-4-2-1-3-36(37)25-53)48(56)54-43(49(57)58)20-30-5-10-33(11-6-30)34-12-7-31(24-52)8-13-34/h1-19,22-23,43-44,47H,20-21,26-29H2,(H,54,56)(H,57,58)/t43-,44-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	657	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189944 (US9175003, 40) Show SMILES Cn1ccnc1CN1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H39Cl2N5O6/c1-52-17-16-50-44(52)25-53-24-35-22-42-41(58-27-43(59-42)33-11-13-36(14-12-33)57-26-30-6-15-37(47)38(48)18-30)21-34(35)20-40(53)45(54)51-39(46(55)56)19-28-2-7-31(8-3-28)32-9-4-29(23-49)5-10-32/h2-18,21-22,39-40,43H,19-20,24-27H2,1H3,(H,51,54)(H,55,56)/t39-,40-,43?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	310	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189945 (US9175003, 51) Show SMILES OC(=O)[C@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)NC(=O)[C@@H]1Cc2cc3NCC(Oc3cc2CN1C(=O)c1ccccc1)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C48H38Cl2N4O6/c49-39-19-10-31(20-40(39)50)28-59-38-17-15-34(16-18-38)45-26-52-41-22-36-23-43(54(27-37(36)24-44(41)60-45)47(56)35-4-2-1-3-5-35)46(55)53-42(48(57)58)21-29-6-11-32(12-7-29)33-13-8-30(25-51)9-14-33/h1-20,22,24,42-43,45,52H,21,23,26-28H2,(H,53,55)(H,57,58)/t42-,43-,45?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	410	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189946 (US9175003, 53) Show SMILES CC(=O)N1CC(Oc2cc3CN([C@@H](Cc3cc12)C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)C(=O)c1ccccc1)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H40Cl2N4O7/c1-30(57)55-28-47(36-16-18-40(19-17-36)62-29-33-11-20-41(51)42(52)21-33)63-46-25-39-27-56(49(59)37-5-3-2-4-6-37)45(24-38(39)23-44(46)55)48(58)54-43(50(60)61)22-31-7-12-34(13-8-31)35-14-9-32(26-53)10-15-35/h2-21,23,25,43,45,47H,22,24,27-29H2,1H3,(H,54,58)(H,60,61)/t43-,45-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	380	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189947 (US9175003, 55) Show SMILES Cc1nc(NC(=O)C2CCC2)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H43Cl2N5O9S2/c1-28-49(67-50(54-28)56-46(58)35-3-2-4-35)68(62,63)57-25-37-23-44-43(65-27-45(66-44)34-14-16-38(17-15-34)64-26-31-9-18-39(51)40(52)19-31)22-36(37)21-42(57)47(59)55-41(48(60)61)20-29-5-10-32(11-6-29)33-12-7-30(24-53)8-13-33/h5-19,22-23,35,41-42,45H,2-4,20-21,25-27H2,1H3,(H,55,59)(H,60,61)(H,54,56,58)/t41-,42-,45?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	360	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189948 (US9175003, 60) Show SMILES Cc1nc(N)sc1S(=O)(=O)N1Cc2cc3O[C@@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C45H37Cl2N5O8S2/c1-25-44(61-45(49)50-25)62(56,57)52-22-33-20-40-39(59-24-41(60-40)31-11-13-34(14-12-31)58-23-28-6-15-35(46)36(47)16-28)19-32(33)18-38(52)42(53)51-37(43(54)55)17-26-2-7-29(8-3-26)30-9-4-27(21-48)5-10-30/h2-16,19-20,37-38,41H,17-18,22-24H2,1H3,(H2,49,50)(H,51,53)(H,54,55)/t37-,38-,41-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	109	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189949 (US9175003, 61) Show SMILES CNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3O[C@@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H39Cl2N5O8S2/c1-26-45(62-46(50-2)51-26)63(57,58)53-23-34-21-41-40(60-25-42(61-41)32-12-14-35(15-13-32)59-24-29-7-16-36(47)37(48)17-29)20-33(34)19-39(53)43(54)52-38(44(55)56)18-27-3-8-30(9-4-27)31-10-5-28(22-49)6-11-31/h3-17,20-21,38-39,42H,18-19,23-25H2,1-2H3,(H,50,51)(H,52,54)(H,55,56)/t38-,39-,42-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	73	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189950 (US9175003, 62) Show SMILES CCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3O[C@@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C47H41Cl2N5O8S2/c1-3-51-47-52-27(2)46(63-47)64(58,59)54-24-35-22-42-41(61-26-43(62-42)33-13-15-36(16-14-33)60-25-30-8-17-37(48)38(49)18-30)21-34(35)20-40(54)44(55)53-39(45(56)57)19-28-4-9-31(10-5-28)32-11-6-29(23-50)7-12-32/h4-18,21-22,39-40,43H,3,19-20,24-26H2,1-2H3,(H,51,52)(H,53,55)(H,56,57)/t39-,40-,43-/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	328	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189951 (US9175003, 63) Show SMILES CCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(C)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C48H44ClN5O8S2/c1-4-51-48-52-29(3)47(63-48)64(58,59)54-25-37-23-43-42(61-27-44(62-43)35-15-17-38(18-16-35)60-26-32-6-5-28(2)39(49)19-32)22-36(37)21-41(54)45(55)53-40(46(56)57)20-30-7-11-33(12-8-30)34-13-9-31(24-50)10-14-34/h5-19,22-23,40-41,44H,4,20-21,25-27H2,1-3H3,(H,51,52)(H,53,55)(H,56,57)/t40-,41-,44?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	277	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189952 (US9175003, 65) Show SMILES Cc1nc(N)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(C)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H40ClN5O8S2/c1-26-3-4-30(17-37(26)47)24-58-36-15-13-33(14-16-36)42-25-59-40-20-34-19-39(52(23-35(34)21-41(40)60-42)62(56,57)45-27(2)50-46(49)61-45)43(53)51-38(44(54)55)18-28-5-9-31(10-6-28)32-11-7-29(22-48)8-12-32/h3-17,20-21,38-39,42H,18-19,23-25H2,1-2H3,(H2,49,50)(H,51,53)(H,54,55)/t38-,39-,42?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	434	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189953 (US9175003, 70) Show SMILES Cc1nc(NC(=O)C(F)(F)F)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C47H36Cl2F3N5O9S2/c1-25-44(67-46(54-25)56-45(61)47(50,51)52)68(62,63)57-22-33-20-40-39(65-24-41(66-40)31-11-13-34(14-12-31)64-23-28-6-15-35(48)36(49)16-28)19-32(33)18-38(57)42(58)55-37(43(59)60)17-26-2-7-29(8-3-26)30-9-4-27(21-53)5-10-30/h2-16,19-20,37-38,41H,17-18,22-24H2,1H3,(H,55,58)(H,59,60)(H,54,56,61)/t37-,38-,41?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	259	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189954 (US9175003, 71) Show SMILES Cc1nc(NC(=O)[C@@H]2CCCN2)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H44Cl2N6O9S2/c1-28-49(68-50(55-28)57-46(59)40-3-2-18-54-40)69(63,64)58-25-36-23-44-43(66-27-45(67-44)34-13-15-37(16-14-34)65-26-31-8-17-38(51)39(52)19-31)22-35(36)21-42(58)47(60)56-41(48(61)62)20-29-4-9-32(10-5-29)33-11-6-30(24-53)7-12-33/h4-17,19,22-23,40-42,45,54H,2-3,18,20-21,25-27H2,1H3,(H,56,60)(H,61,62)(H,55,57,59)/t40-,41-,42-,45?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	477	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189955 (US9175003, 72) Show SMILES CC[C@H](N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1)c1ccccc1 |r| Show InChI InChI=1S/C50H43Cl2N3O6/c1-2-44(36-6-4-3-5-7-36)55-28-39-26-47-46(60-30-48(61-47)37-17-19-40(20-18-37)59-29-33-12-21-41(51)42(52)22-33)25-38(39)24-45(55)49(56)54-43(50(57)58)23-31-8-13-34(14-9-31)35-15-10-32(27-53)11-16-35/h3-22,25-26,43-45,48H,2,23-24,28-30H2,1H3,(H,54,56)(H,57,58)/t43-,44-,45-,48+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	480	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189956 (US9175003, 73) Show SMILES CC[C@H](N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccncc1)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1)c1ccccc1 |r| Show InChI InChI=1S/C48H43Cl2N3O6/c1-2-42(34-6-4-3-5-7-34)53-27-37-26-45-44(58-29-46(59-45)35-13-15-38(16-14-35)57-28-31-10-17-39(49)40(50)22-31)25-36(37)24-43(53)47(54)52-41(48(55)56)23-30-8-11-32(12-9-30)33-18-20-51-21-19-33/h3-22,25-26,41-43,46H,2,23-24,27-29H2,1H3,(H,52,54)(H,55,56)/t41-,42-,43-,46+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	76	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189957 (US9175003, 81) Show SMILES Cc1nc(N)sc1S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C45H37Cl2N5O8S2/c1-25-44(61-45(49)50-25)62(56,57)52-22-33-20-40-39(59-24-41(60-40)31-11-13-34(14-12-31)58-23-28-6-15-35(46)36(47)16-28)19-32(33)18-38(52)42(53)51-37(43(54)55)17-26-2-7-29(8-3-26)30-9-4-27(21-48)5-10-30/h2-16,19-20,37-38,41H,17-18,22-24H2,1H3,(H2,49,50)(H,51,53)(H,54,55)/t37-,38-,41+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	326	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189958 (US9175003, 85) Show SMILES CNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H39Cl2N5O8S2/c1-26-45(62-46(50-2)51-26)63(57,58)53-23-34-21-41-40(60-25-42(61-41)32-12-14-35(15-13-32)59-24-29-7-16-36(47)37(48)17-29)20-33(34)19-39(53)43(54)52-38(44(55)56)18-27-3-8-30(9-4-27)31-10-5-28(22-49)6-11-31/h3-17,20-21,38-39,42H,18-19,23-25H2,1-2H3,(H,50,51)(H,52,54)(H,55,56)/t38-,39-,42+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	263	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189959 (US9175003, 86) Show SMILES CCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C47H41Cl2N5O8S2/c1-3-51-47-52-27(2)46(63-47)64(58,59)54-24-35-22-42-41(61-26-43(62-42)33-13-15-36(16-14-33)60-25-30-8-17-37(48)38(49)18-30)21-34(35)20-40(54)44(55)53-39(45(56)57)19-28-4-9-31(10-5-28)32-11-6-29(23-50)7-12-32/h4-18,21-22,39-40,43H,3,19-20,24-26H2,1-2H3,(H,51,52)(H,53,55)(H,56,57)/t39-,40-,43+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	249	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189960 (US9175003, 87) Show SMILES CCCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C48H43Cl2N5O8S2/c1-3-18-52-48-53-28(2)47(64-48)65(59,60)55-25-36-23-43-42(62-27-44(63-43)34-13-15-37(16-14-34)61-26-31-8-17-38(49)39(50)19-31)22-35(36)21-41(55)45(56)54-40(46(57)58)20-29-4-9-32(10-5-29)33-11-6-30(24-51)7-12-33/h4-17,19,22-23,40-41,44H,3,18,20-21,25-27H2,1-2H3,(H,52,53)(H,54,56)(H,57,58)/t40-,41-,44?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	67	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189961 (US9175003, 88) Show SMILES Cc1nc(NCC2CC2)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H43Cl2N5O8S2/c1-28-48(65-49(54-28)53-24-31-2-3-31)66(60,61)56-25-37-22-44-43(63-27-45(64-44)35-13-15-38(16-14-35)62-26-32-8-17-39(50)40(51)18-32)21-36(37)20-42(56)46(57)55-41(47(58)59)19-29-4-9-33(10-5-29)34-11-6-30(23-52)7-12-34/h4-18,21-22,31,41-42,45H,2-3,19-20,24-27H2,1H3,(H,53,54)(H,55,57)(H,58,59)/t41-,42-,45?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	75	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189962 (US9175003, 92) Show SMILES COCCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C48H43Cl2N5O9S2/c1-28-47(65-48(53-28)52-17-18-61-2)66(59,60)55-25-36-23-43-42(63-27-44(64-43)34-12-14-37(15-13-34)62-26-31-7-16-38(49)39(50)19-31)22-35(36)21-41(55)45(56)54-40(46(57)58)20-29-3-8-32(9-4-29)33-10-5-30(24-51)6-11-33/h3-16,19,22-23,40-41,44H,17-18,20-21,25-27H2,1-2H3,(H,52,53)(H,54,56)(H,57,58)/t40-,41-,44+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	156	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189963 (US9175003, 95) Show SMILES Cc1sc(N)nc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C45H37Cl2N5O8S2/c1-25-43(51-45(49)61-25)62(56,57)52-22-33-20-40-39(59-24-41(60-40)31-11-13-34(14-12-31)58-23-28-6-15-35(46)36(47)16-28)19-32(33)18-38(52)42(53)50-37(44(54)55)17-26-2-7-29(8-3-26)30-9-4-27(21-48)5-10-30/h2-16,19-20,37-38,41H,17-18,22-24H2,1H3,(H2,49,51)(H,50,53)(H,54,55)/t37-,38-,41?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	462	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189964 (US9175003, 96) Show SMILES CCNc1nc(c(C)s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C47H41Cl2N5O8S2/c1-3-51-47-53-45(27(2)63-47)64(58,59)54-24-35-22-42-41(61-26-43(62-42)33-13-15-36(16-14-33)60-25-30-8-17-37(48)38(49)18-30)21-34(35)20-40(54)44(55)52-39(46(56)57)19-28-4-9-31(10-5-28)32-11-6-29(23-50)7-12-32/h4-18,21-22,39-40,43H,3,19-20,24-26H2,1-2H3,(H,51,53)(H,52,55)(H,56,57)/t39-,40-,43?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	185	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189965 (US9175003, 98) Show SMILES COc1cc(C)ccc1S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H41Cl2N3O9S/c1-29-3-18-47(45(19-29)60-2)64(58,59)54-26-37-24-44-43(62-28-46(63-44)35-13-15-38(16-14-35)61-27-32-8-17-39(50)40(51)20-32)23-36(37)22-42(54)48(55)53-41(49(56)57)21-30-4-9-33(10-5-30)34-11-6-31(25-52)7-12-34/h3-20,23-24,41-42,46H,21-22,26-28H2,1-2H3,(H,53,55)(H,56,57)/t41-,42-,46+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	377	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189966 (US9175003, 105) Show SMILES Cc1nc(NCC2CCC2)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H45Cl2N5O8S2/c1-29-49(66-50(55-29)54-25-32-3-2-4-32)67(61,62)57-26-38-23-45-44(64-28-46(65-45)36-14-16-39(17-15-36)63-27-33-9-18-40(51)41(52)19-33)22-37(38)21-43(57)47(58)56-42(48(59)60)20-30-5-10-34(11-6-30)35-12-7-31(24-53)8-13-35/h5-19,22-23,32,42-43,46H,2-4,20-21,25-28H2,1H3,(H,54,55)(H,56,58)(H,59,60)/t42-,43-,46?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	321	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189967 (US9175003, 108) Show SMILES Cc1nc(NC2CCCC2)sc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H45Cl2N5O8S2/c1-29-49(66-50(54-29)55-38-4-2-3-5-38)67(61,62)57-26-37-24-45-44(64-28-46(65-45)35-15-17-39(18-16-35)63-27-32-10-19-40(51)41(52)20-32)23-36(37)22-43(57)47(58)56-42(48(59)60)21-30-6-11-33(12-7-30)34-13-8-31(25-53)9-14-34/h6-20,23-24,38,42-43,46H,2-5,21-22,26-28H2,1H3,(H,54,55)(H,56,58)(H,59,60)/t42-,43-,46?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	70	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189968 (US9175003, 109) Show SMILES CCCCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H45Cl2N5O8S2/c1-3-4-19-53-49-54-29(2)48(65-49)66(60,61)56-26-37-24-44-43(63-28-45(64-44)35-14-16-38(17-15-35)62-27-32-9-18-39(50)40(51)20-32)23-36(37)22-42(56)46(57)55-41(47(58)59)21-30-5-10-33(11-6-30)34-12-7-31(25-52)8-13-34/h5-18,20,23-24,41-42,45H,3-4,19,21-22,26-28H2,1-2H3,(H,53,54)(H,55,57)(H,58,59)/t41-,42-,45?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	298	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189969 (US9175003, 110) Show SMILES CC(C)CCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H47Cl2N5O8S2/c1-29(2)18-19-54-50-55-30(3)49(66-50)67(61,62)57-26-38-24-45-44(64-28-46(65-45)36-13-15-39(16-14-36)63-27-33-8-17-40(51)41(52)20-33)23-37(38)22-43(57)47(58)56-42(48(59)60)21-31-4-9-34(10-5-31)35-11-6-32(25-53)7-12-35/h4-17,20,23-24,29,42-43,46H,18-19,21-22,26-28H2,1-3H3,(H,54,55)(H,56,58)(H,59,60)/t42-,43-,46?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	356	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189970 (US9175003, 111) Show SMILES CC(=O)Nc1ccc(c(C)c1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H42Cl2N4O9S/c1-29-19-39(54-30(2)57)14-18-48(29)66(61,62)56-26-38-24-46-45(64-28-47(65-46)36-12-15-40(16-13-36)63-27-33-7-17-41(51)42(52)20-33)23-37(38)22-44(56)49(58)55-43(50(59)60)21-31-3-8-34(9-4-31)35-10-5-32(25-53)6-11-35/h3-20,23-24,43-44,47H,21-22,26-28H2,1-2H3,(H,54,57)(H,55,58)(H,59,60)/t43-,44-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	44	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189971 (US9175003, 112) Show SMILES OC(=O)[C@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)NC(=O)[C@@H]1Cc2cc3OCC(Oc3cc2CN1S(=O)(=O)c1ccc(nc1)N1CCOCC1)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H43Cl2N5O9S/c51-41-15-5-33(21-42(41)52)29-64-39-12-10-36(11-13-39)47-30-65-45-24-37-23-44(49(58)55-43(50(59)60)22-31-1-6-34(7-2-31)35-8-3-32(26-53)4-9-35)57(28-38(37)25-46(45)66-47)67(61,62)40-14-16-48(54-27-40)56-17-19-63-20-18-56/h1-16,21,24-25,27,43-44,47H,17-20,22-23,28-30H2,(H,55,58)(H,59,60)/t43-,44-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	48	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189972 (US9175003, 114) Show SMILES CC(C)C(=O)Nc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H43Cl2N5O9S2/c1-27(2)45(57)55-49-53-28(3)48(66-49)67(61,62)56-24-36-22-43-42(64-26-44(65-43)34-13-15-37(16-14-34)63-25-31-8-17-38(50)39(51)18-31)21-35(36)20-41(56)46(58)54-40(47(59)60)19-29-4-9-32(10-5-29)33-11-6-30(23-52)7-12-33/h4-18,21-22,27,40-41,44H,19-20,24-26H2,1-3H3,(H,54,58)(H,59,60)(H,53,55,57)/t40-,41-,44?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	232	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189973 (US9175003, 115) Show SMILES CC(=O)Nc1ccc(cc1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H40Cl2N4O9S/c1-29(56)53-38-13-17-40(18-14-38)65(60,61)55-26-37-24-46-45(63-28-47(64-46)35-11-15-39(16-12-35)62-27-32-6-19-41(50)42(51)20-32)23-36(37)22-44(55)48(57)54-43(49(58)59)21-30-2-7-33(8-3-30)34-9-4-31(25-52)5-10-34/h2-20,23-24,43-44,47H,21-22,26-28H2,1H3,(H,53,56)(H,54,57)(H,58,59)/t43-,44-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	163	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189974 (US9175003, 119) Show SMILES CCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(F)cc1)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H41Cl2FN4O8S2/c1-3-50-46-51-26(2)45(62-46)63(57,58)53-23-33-22-41-40(60-25-42(61-41)31-11-15-35(16-12-31)59-24-28-6-17-36(47)37(48)18-28)21-32(33)20-39(53)43(54)52-38(44(55)56)19-27-4-7-29(8-5-27)30-9-13-34(49)14-10-30/h4-18,21-22,38-39,42H,3,19-20,23-25H2,1-2H3,(H,50,51)(H,52,54)(H,55,56)/t38-,39-,42?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	131	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189975 (US9175003, 120) Show SMILES CCNc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(Cl)cc1)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H41Cl3N4O8S2/c1-3-50-46-51-26(2)45(62-46)63(57,58)53-23-33-22-41-40(60-25-42(61-41)31-11-15-35(16-12-31)59-24-28-6-17-36(48)37(49)18-28)21-32(33)20-39(53)43(54)52-38(44(55)56)19-27-4-7-29(8-5-27)30-9-13-34(47)14-10-30/h4-18,21-22,38-39,42H,3,19-20,23-25H2,1-2H3,(H,50,51)(H,52,54)(H,55,56)/t38-,39-,42?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	264	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189976 (US9175003, 126) Show SMILES Cc1nc(N)sc1C(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H37Cl2N5O7S/c1-25-42(61-46(50)51-25)44(55)53-22-33-20-40-39(59-24-41(60-40)31-11-13-34(14-12-31)58-23-28-6-15-35(47)36(48)16-28)19-32(33)18-38(53)43(54)52-37(45(56)57)17-26-2-7-29(8-3-26)30-9-4-27(21-49)5-10-30/h2-16,19-20,37-38,41H,17-18,22-24H2,1H3,(H2,50,51)(H,52,54)(H,56,57)/t37-,38-,41?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	n/a	n/a	312	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189977 (US9175003, 128) Show SMILES Cc1noc(C)c1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H38Cl2N4O9S/c1-26-44(27(2)61-51-26)62(56,57)52-23-35-21-42-41(59-25-43(60-42)33-12-14-36(15-13-33)58-24-30-7-16-37(47)38(48)17-30)20-34(35)19-40(52)45(53)50-39(46(54)55)18-28-3-8-31(9-4-28)32-10-5-29(22-49)6-11-32/h3-17,20-21,39-40,43H,18-19,23-25H2,1-2H3,(H,50,53)(H,54,55)/t39-,40-,43?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	178	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189978 (US9175003, 130) Show SMILES Cc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C46H38Cl2N4O8S2/c1-26-46(61-27(2)50-26)62(56,57)52-23-35-21-42-41(59-25-43(60-42)33-12-14-36(15-13-33)58-24-30-7-16-37(47)38(48)17-30)20-34(35)19-40(52)44(53)51-39(45(54)55)18-28-3-8-31(9-4-28)32-10-5-29(22-49)6-11-32/h3-17,20-21,39-40,43H,18-19,23-25H2,1-2H3,(H,51,53)(H,54,55)/t39-,40-,43?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	111	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189979 (US9175003, 132) Show SMILES CCC(=O)Nc1nc(C)c(s1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C48H41Cl2N5O9S2/c1-3-44(56)54-48-52-27(2)47(65-48)66(60,61)55-24-35-22-42-41(63-26-43(64-42)33-13-15-36(16-14-33)62-25-30-8-17-37(49)38(50)18-30)21-34(35)20-40(55)45(57)53-39(46(58)59)19-28-4-9-31(10-5-28)32-11-6-29(23-51)7-12-32/h4-18,21-22,39-40,43H,3,19-20,24-26H2,1-2H3,(H,53,57)(H,58,59)(H,52,54,56)/t39-,40-,43?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	214	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189980 (US9175003, 133) Show SMILES Cc1nc(ccc1S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1)N1CCOCC1 |r| Show InChI InChI=1S/C51H45Cl2N5O9S/c1-31-48(16-17-49(55-31)57-18-20-64-21-19-57)68(62,63)58-28-39-26-46-45(66-30-47(67-46)37-11-13-40(14-12-37)65-29-34-6-15-41(52)42(53)22-34)25-38(39)24-44(58)50(59)56-43(51(60)61)23-32-2-7-35(8-3-32)36-9-4-33(27-54)5-10-36/h2-17,22,25-26,43-44,47H,18-21,23-24,28-30H2,1H3,(H,56,59)(H,60,61)/t43-,44-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	54	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189981 (US9175003, 135) Show SMILES CCNc1ccc(c(C)n1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C49H43Cl2N5O8S/c1-3-53-47-19-18-46(29(2)54-47)65(60,61)56-26-37-24-44-43(63-28-45(64-44)35-13-15-38(16-14-35)62-27-32-8-17-39(50)40(51)20-32)23-36(37)22-42(56)48(57)55-41(49(58)59)21-30-4-9-33(10-5-30)34-11-6-31(25-52)7-12-34/h4-20,23-24,41-42,45H,3,21-22,26-28H2,1-2H3,(H,53,54)(H,55,57)(H,58,59)/t41-,42-,45?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	284	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189982 (US9175003, 136) Show SMILES COCCNc1ccc(c(C)n1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H45Cl2N5O9S/c1-30-47(17-18-48(55-30)54-19-20-63-2)67(61,62)57-27-38-25-45-44(65-29-46(66-45)36-12-14-39(15-13-36)64-28-33-7-16-40(51)41(52)21-33)24-37(38)23-43(57)49(58)56-42(50(59)60)22-31-3-8-34(9-4-31)35-10-5-32(26-53)6-11-35/h3-18,21,24-25,42-43,46H,19-20,22-23,27-29H2,1-2H3,(H,54,55)(H,56,58)(H,59,60)/t42-,43-,46?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	50	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189983 (US9175003, 138) Show SMILES CC(=O)Nc1nc(cs1)-c1ccc(cc1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C52H41Cl2N5O9S2/c1-30(60)56-52-58-45(29-69-52)36-13-17-41(18-14-36)70(64,65)59-26-39-24-48-47(67-28-49(68-48)37-11-15-40(16-12-37)66-27-33-6-19-42(53)43(54)20-33)23-38(39)22-46(59)50(61)57-44(51(62)63)21-31-2-7-34(8-3-31)35-9-4-32(25-55)5-10-35/h2-20,23-24,29,44,46,49H,21-22,26-28H2,1H3,(H,57,61)(H,62,63)(H,56,58,60)/t44-,46-,49?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	241	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189984 (US9175003, 139) Show SMILES Nc1nc(cs1)-c1ccc(cc1)S(=O)(=O)N1Cc2cc3OC(COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H39Cl2N5O8S2/c51-40-18-5-31(19-41(40)52)26-63-38-14-10-35(11-15-38)47-27-64-45-22-36-21-44(48(58)55-42(49(59)60)20-29-1-6-32(7-2-29)33-8-3-30(24-53)4-9-33)57(25-37(36)23-46(45)65-47)67(61,62)39-16-12-34(13-17-39)43-28-66-50(54)56-43/h1-19,22-23,28,42,44,47H,20-21,25-27H2,(H2,54,56)(H,55,58)(H,59,60)/t42-,44-,47?/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	85	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189985 (US9175003, 141) Show SMILES Cc1nc(N)ccc1S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C47H39Cl2N5O8S/c1-27-44(16-17-45(51)52-27)63(58,59)54-24-35-22-42-41(61-26-43(62-42)33-11-13-36(14-12-33)60-25-30-6-15-37(48)38(49)18-30)21-34(35)20-40(54)46(55)53-39(47(56)57)19-28-2-7-31(8-3-28)32-9-4-29(23-50)5-10-32/h2-18,21-22,39-40,43H,19-20,24-26H2,1H3,(H2,51,52)(H,53,55)(H,56,57)/t39-,40-,43+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	315	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189986 (US9175003, 142) Show SMILES CC(C)Nc1ccc(c(C)n1)S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C50H45Cl2N5O8S/c1-29(2)54-48-19-18-47(30(3)55-48)66(61,62)57-26-38-24-45-44(64-28-46(65-45)36-13-15-39(16-14-36)63-27-33-8-17-40(51)41(52)20-33)23-37(38)22-43(57)49(58)56-42(50(59)60)21-31-4-9-34(10-5-31)35-11-6-32(25-53)7-12-35/h4-20,23-24,29,42-43,46H,21-22,26-28H2,1-3H3,(H,54,55)(H,56,58)(H,59,60)/t42-,43-,46+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	263	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189987 (US9175003, 144) Show SMILES Cc1nc(NCC2CC2)ccc1S(=O)(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccc(cc1)C#N)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C51H45Cl2N5O8S/c1-30-48(18-19-49(56-30)55-26-33-2-3-33)67(62,63)58-27-39-24-46-45(65-29-47(66-46)37-13-15-40(16-14-37)64-28-34-8-17-41(52)42(53)20-34)23-38(39)22-44(58)50(59)57-43(51(60)61)21-31-4-9-35(10-5-31)36-11-6-32(25-54)7-12-36/h4-20,23-24,33,43-44,47H,2-3,21-22,26-29H2,1H3,(H,55,56)(H,57,59)(H,60,61)/t43-,44-,47+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	245	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189988 (US9175003, 147) Show SMILES CC[C@H](N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccnc(C)c1C)C(O)=O)c1ccc(OCc2cccc(Cl)c2)cc1)c1ccccc1 |r| Show InChI InChI=1S/C50H48ClN3O6/c1-4-44(36-10-6-5-7-11-36)54-28-39-27-47-46(59-30-48(60-47)37-17-19-41(20-18-37)58-29-34-9-8-12-40(51)23-34)26-38(39)25-45(54)49(55)53-43(50(56)57)24-33-13-15-35(16-14-33)42-21-22-52-32(3)31(42)2/h5-23,26-27,43-45,48H,4,24-25,28-30H2,1-3H3,(H,53,55)(H,56,57)/t43-,44-,45-,48+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	5	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189989 (US9175003, 148 | US9175003, 179) Show SMILES CC[C@H](N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccnc(C)c1C)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1)c1ccccc1 |r| Show InChI InChI=1S/C50H47Cl2N3O6/c1-4-44(35-8-6-5-7-9-35)55-27-38-26-47-46(60-29-48(61-47)36-15-17-39(18-16-36)59-28-33-12-19-41(51)42(52)22-33)25-37(38)24-45(55)49(56)54-43(50(57)58)23-32-10-13-34(14-11-32)40-20-21-53-31(3)30(40)2/h5-22,25-26,43-45,48H,4,23-24,27-29H2,1-3H3,(H,54,56)(H,57,58)/t43-,44-,45-,48+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	Purchase MCE PC cid PC sid PDB UniChem Similars	US Patent	n/a	n/a	n/a	n/a	13	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189990 (US9175003, 149) Show SMILES CC[C@H](N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccnc(C)c1C)C(O)=O)c1ccc(OCc2ccccc2)cc1)c1ccccc1 |r| Show InChI InChI=1S/C50H49N3O6/c1-4-44(37-13-9-6-10-14-37)53-29-40-28-47-46(58-31-48(59-47)38-19-21-41(22-20-38)57-30-35-11-7-5-8-12-35)27-39(40)26-45(53)49(54)52-43(50(55)56)25-34-15-17-36(18-16-34)42-23-24-51-33(3)32(42)2/h5-24,27-28,43-45,48H,4,25-26,29-31H2,1-3H3,(H,52,54)(H,55,56)/t43-,44-,45-,48+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	26	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair
Glucagon-like peptide 1 receptor (Homo sapiens (Human))	BDBM189991 (US9175003, 150) Show SMILES CC(=O)N1Cc2cc3O[C@H](COc3cc2C[C@H]1C(=O)N[C@@H](Cc1ccc(cc1)-c1ccnc(C)c1C)C(O)=O)c1ccc(OCc2ccc(Cl)c(Cl)c2)cc1 |r| Show InChI InChI=1S/C43H39Cl2N3O7/c1-24-25(2)46-15-14-34(24)29-7-4-27(5-8-29)17-37(43(51)52)47-42(50)38-18-31-19-39-40(20-32(31)21-48(38)26(3)49)55-41(23-54-39)30-9-11-33(12-10-30)53-22-28-6-13-35(44)36(45)16-28/h4-16,19-20,37-38,41H,17-18,21-23H2,1-3H3,(H,47,50)(H,51,52)/t37-,38-,41+/m0/s1	PDB UniProtKB/SwissProt antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem Similars	US Patent	n/a	n/a	n/a	n/a	372	n/a	n/a	n/a	n/a
vTv Therapeutics LLC US Patent					Assay Description The efficacy of GLP-1 receptor agonists was studied in a cAMP functional assay using HEK-293 Cells expressing the cloned human GLP-1 receptor. GLP-1-...				US Patent US9175003 (2015) BindingDB Entry DOI: 10.7270/Q27943FG
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 234 total )  |  Next  |  Last  >>

Jump to: